Mary Slack

10.6k total citations · 4 hit papers
160 papers, 7.7k citations indexed

About

Mary Slack is a scholar working on Epidemiology, Microbiology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Mary Slack has authored 160 papers receiving a total of 7.7k indexed citations (citations by other indexed papers that have themselves been cited), including 123 papers in Epidemiology, 77 papers in Microbiology and 14 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Mary Slack's work include Pneumonia and Respiratory Infections (115 papers), Bacterial Infections and Vaccines (76 papers) and Respiratory viral infections research (54 papers). Mary Slack is often cited by papers focused on Pneumonia and Respiratory Infections (115 papers), Bacterial Infections and Vaccines (76 papers) and Respiratory viral infections research (54 papers). Mary Slack collaborates with scholars based in United Kingdom, Australia and United States. Mary Slack's co-authors include Elizabeth Miller, Shamez Ladhani, Pauline A. Waight, Mary Ramsay, Robert C. George, Nicholas J. Andrews, Nick Andrews, Carmen Sheppard, Paul T. Heath and Wright W. Nichols and has published in prestigious journals such as New England Journal of Medicine, The Lancet and JAMA.

In The Last Decade

Mary Slack

157 papers receiving 7.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Bacteremia among Children Admitted to a Rural Hospital in Kenya

2005 641 citations Mary Slack et al. profile →
Herd immunity and serotype replacement 4 years after seven-valent pneumococcal conjugate vaccination in England and Wales: an observational cohort study

2011 517 citations Elizabeth Miller, Nicholas J. Andrews et al. The Lancet Infectious Diseases profile →
Effect of the 13-valent pneumococcal conjugate vaccine on invasive pneumococcal disease in England and Wales 4 years after its introduction: an observational cohort study

2015 455 citations Pauline A. Waight, Nicholas J. Andrews et al. The Lancet Infectious Diseases profile →
Serotype-specific effectiveness and correlates of protection for the 13-valent pneumococcal conjugate vaccine: a postlicensure indirect cohort study

2014 393 citations Nick Andrews, Pauline A. Waight et al. The Lancet Infectious Diseases profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Mary Slack United Kingdom	44	5.7k	3.4k	709	685	670	160	7.7k
Margaret R. Hammerschlag United States	44	3.7k 0.6×	3.9k 1.1×	815 1.1×	613 0.9×	507 0.8×	219	6.9k
David E. Soper United States	43	4.1k 0.7×	2.7k 0.8×	1.4k 1.9×	632 0.9×	412 0.6×	172	7.5k
E. Arne Høiby Norway	39	3.8k 0.7×	3.6k 1.1×	1.0k 1.4×	1.0k 1.5×	575 0.9×	155	6.0k
Joel I. Ward United States	44	5.0k 0.9×	3.1k 0.9×	619 0.9×	1.7k 2.4×	256 0.4×	138	6.8k
Birger Trollfors Sweden	39	3.2k 0.6×	2.3k 0.7×	804 1.1×	1.3k 1.8×	214 0.3×	200	5.4k
Stuart C. Clarke United Kingdom	33	2.6k 0.5×	1.5k 0.4×	435 0.6×	684 1.0×	667 1.0×	179	4.3k
Thomas Cherian India	32	4.4k 0.8×	1.6k 0.5×	617 0.9×	972 1.4×	265 0.4×	106	6.1k
Hans O. Hallander Sweden	41	3.3k 0.6×	2.9k 0.8×	365 0.5×	1.3k 1.9×	504 0.8×	124	5.0k
Robert Austrian United States	40	7.3k 1.3×	3.2k 0.9×	1.2k 1.6×	894 1.3×	749 1.1×	118	9.3k
J. Pekka Nuorti Finland	37	3.7k 0.6×	1.3k 0.4×	560 0.8×	776 1.1×	303 0.5×	89	5.5k

Countries citing papers authored by Mary Slack

Since Specialization

Citations

This map shows the geographic impact of Mary Slack's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mary Slack with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mary Slack more than expected).

Fields of papers citing papers by Mary Slack

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mary Slack. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mary Slack. The network helps show where Mary Slack may publish in the future.

Co-authorship network of co-authors of Mary Slack

This figure shows the co-authorship network connecting the top 25 collaborators of Mary Slack. A scholar is included among the top collaborators of Mary Slack based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mary Slack. Mary Slack is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Grant, Lindsay R., Germaine Hanquet, Christian Theilacker, et al.. (2024). Effects of PCV10 and PCV13 on pneumococcal serotype 6C disease, carriage, and antimicrobial resistance. Vaccine. 42(12). 2983–2993. 6 indexed citations

Dunne, Eileen M., Marta C. Nunes, Mary Slack, Christian Theilacker, & Bradford D. Gessner. (2023). Effects of pneumococcal conjugate vaccines on reducing the risk of respiratory disease associated with coronavirus infection. SHILAP Revista de lepidopterología. 15(1). 10–10. 6 indexed citations

Méroc, Estelle, Mark A. Fletcher, Germaine Hanquet, et al.. (2023). Systematic Literature Review of the Epidemiological Characteristics of Pneumococcal Disease Caused by the Additional Serotypes Covered by the 20-Valent Pneumococcal Conjugate Vaccine. Microorganisms. 11(7). 1816–1816. 9 indexed citations

Mendes, Diana, Mark Atwood, Reiko Sato, et al.. (2023). OP78 Cost-effectiveness Of A 20-valent Pneumococcal Conjugate Vaccine To Directly Protect Adults Against Pneumococcal Disease In England. International Journal of Technology Assessment in Health Care. 39(S1). S20–S21.

Grant, Lindsay R., Mary Slack, Christian Theilacker, et al.. (2023). Distribution of serotypes causing invasive pneumococcal disease in older adults from high-income countries and impact of pediatric and adult vaccination policies. Vaccine. 41(38). 5662–5669. 11 indexed citations

Slack, Mary. (2021). Long Term Impact of Conjugate Vaccines on Haemophilus influenzae Meningitis: Narrative Review. Microorganisms. 9(5). 886–886. 17 indexed citations

Vyse, Andrew, James Campling, Carole Czudek, et al.. (2021). A review of current data to support decision making for introduction of next generation higher valency pneumococcal conjugate vaccination of immunocompetent older adults in the UK. Expert Review of Vaccines. 20(10). 1311–1325. 6 indexed citations

Rodrigo, Chamira, Thomas Bewick, Carmen Sheppard, et al.. (2015). Impact of infant 13-valent pneumococcal conjugate vaccine on serotypes in adult pneumonia. European Respiratory Journal. 45(6). 1632–1641. 107 indexed citations

Rodrigo, Chamira, Thomas Bewick, Carmen Sheppard, et al.. (2014). Clinical features of adults with seven-valent-conjugated-vaccine-serotype pneumococcal pneumonia. Vaccine. 32(13). 1460–1465. 7 indexed citations

10.

Miller, Elizabeth, Nicholas J. Andrews, Pauline A. Waight, Mary Slack, & Robert C. George. (2011). Herd immunity and serotype replacement 4 years after seven-valent pneumococcal conjugate vaccination in England and Wales: an observational cohort study. The Lancet Infectious Diseases. 11(10). 760–768. 517 indexed citations breakdown →

11.

Ladhani, Shamez, Paul T. Heath, Mary Ramsay, et al.. (2010). Long-term complications and risk of other serious infections following invasive Haemophilus influenzae serotype b disease in vaccinated children. Vaccine. 28(10). 2195–2200. 9 indexed citations

12.

Ladhani, Shamez, et al.. (2010). InvasiveHaemophilus influenzaeDisease, Europe, 1996–2006. Emerging infectious diseases. 16(3). 455–463. 162 indexed citations

13.

Ladhani, Shamez, et al.. (2009). Long‐Term Immunological Follow‐Up of Children withHaemophilus influenzaeSerotype b Vaccine Failure in the United Kingdom. Clinical Infectious Diseases. 49(3). 372–380. 15 indexed citations

14.

Pichon, Bruno, et al.. (2009). Genetic characteristics of pneumococcal disease in elderly patients before introducing the pneumococcal conjugate vaccine. Epidemiology and Infection. 137(7). 1049–1056. 7 indexed citations

15.

McVernon, Jodie, Nick Andrews, Mary Slack, Richard Moxon, & Mary Ramsay. (2007). Host and environmental factors associated with Hib in England, 1998-2002. Archives of Disease in Childhood. 93(8). 670–675. 19 indexed citations

16.

Sarangi, J, K Cartwright, J Stuart, et al.. (2000). Invasive Haemophilus influenzae disease in adults. Epidemiology and Infection. 124(3). 441–447. 50 indexed citations

17.

Moxon, E. Richard, et al.. (1999). 4th European conference on vaccinology: societal value of vaccination. Vaccine. 17. S11–S13. 20 indexed citations

18.

Jordens, J. Z. & Mary Slack. (1995). Haemophilus influenzae: Then and now. European Journal of Clinical Microbiology & Infectious Diseases. 14(11). 935–948. 63 indexed citations

19.

Clements, Dennis A., Robert Booy, Ron Dagan, et al.. (1993). Comparison of the epidemiology and cost of Haemophilus influenzae type b disease in five western countries. The Pediatric Infectious Disease Journal. 12(5). 362–367. 39 indexed citations

20.

Newman, R J, G.D.W. Curtis, & Mary Slack. (1983). Bursal fluid lactate determination and the diagnosis of bursitis.. BMJ. 286(6383). 2022–2023. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact